Glucotrack, Inc. (GCTK)
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
GlucoTrack, Inc.
NASDAQ:GCTKHealthcare · Medical - Devices
-41.73%$0.8100
Mkt Cap$959K
Float1.09M
O/S1.18M
Vol
$ Vol
RVOL
Inst Own1.6%
SI6.7%
Earnings
Dilution
| Form | Description | Links | |
|---|---|---|---|
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| S-1/A | |||
| PRE 14A | |||
| 425 | |||
| 8-K/A | |||
| 8-K | |||
| 424B5 | |||
| 8-K | |||
| 425 | |||
| 8-K | |||
| 8-K | |||
| S-1 | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 13G | |||
| 8-K | |||
| 425 | |||
| 8-K/A | |||
| 8-K | |||
| DEFA14A | |||
| 8-K |
1-25 of 495 filings
…
Recent SEC filings with analysis
- 8-KGlucotrack (GCTK) received written notice on October 28, 2026 that a Nasdaq Hearings Panel determined to delist its securities after the company's closing bid…
- 8-KGlucotrack closed a $2.0M private placement via senior secured convertible notes ($2.56M principal, 22% OID, 8% interest, 9-month maturity).
- 8-KGlucotrack entered into a Waiver Agreement on October 13, 2026 with holders of warrants issued under its July 14, 2026 Securities Purchase Agreement.
- S-1/AGlucotrack filed an S-1/A registering the resale of up to 43,223,705 shares by selling stockholders, roughly 1,825% of its 2,368,237 shares outstanding.
- 8-KGlucotrack executed amendments to its bridge warrants, PIPE common warrants, September convertible notes, and September warrants starting September 22, 2026,…
- 424B5Glucotrack, Inc.
- 8-KGlucotrack, Inc.
- 8-KGlucotrack, Inc.